GlobeNewswire Inc | Sep 2, 2021 07:00AM EDT

September 02, 2021

LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences:

Citis 16th Annual BioPharma Virtual ConferenceOne-on-one meetings Wednesday, September 8, 2021

Morgan Stanleys 19th Annual Global Healthcare ConferenceOne-on-one meetings Friday, September 10, 2021

H.C. Wainwright 23rd Annual Global Investment ConferenceCorporate presentation On-demand starting on September 13, 2021One-on-one meetings Wednesday, September 15, 2021

During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Companys corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as well as the recent top-line data from Lauriet Phase 2 trial evaluating semorinemab in mild-to-moderate AD.

A webcast of the corporate presentation will be available on the Events Page of AC Immunes website.

About AC Immune SA AC Immune SAis clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins. The Companys two clinically validated technology platforms, SupraAntigenand Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials.AC Immunehas a strong track record of securing strategic partnerships with leading global pharmaceutical companies includingGenentech, a member of the Roche Group, Eli Lilly and Company, andJanssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billionin potential milestone payments.

SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

For further information, please contact:

Media Relations Investor RelationsSaoyuth Nidh Yves Kremer, Ph.D.AC Immune AC ImmunePhone: +41 21 345 91 34 Phone: +41 21 345 91 90Email: saoyuth.nidh@acimmune.com Email: yves.kremer@acimmune.com U.S. Media U.S. InvestorsKatie Gallagher Corey Davis, Ph.D.LaVoie Health Science LifeSci AdvisorsPhone: +1 617 792 3937 Phone: +1 212 915 2577Email: kgallagher@lavoiehealthscience.com Email:cdavis@lifesciadvisors.com

Forward-looking statementsThis press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions Item 3. Key Information Risk Factors and Item 5. Operating and Financial Review and Prospects in AC Immunes Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.